Herlev Hospital
- Address
- Dyrehavevej 29, 3400 Herlev, Denmark
Cardiovascular Diseases
At Herlev Hospital researchers are studying heart‑related conditions such as atrial fibrillation and in‑hospital cardiac arrest. Trials aim to compare new anticoagulants with existing therapy and to test simple interventions that could improve survival during emergencies.
- Evaluating a novel oral anticoagulant for stroke prevention
- Comparing resuscitation outcomes with adjunctive agents
- Assessing safety of new blood‑thinning strategies
- Investigating rapid‑action treatments during cardiac arrest
The department’s cardiovascular program blends cutting‑edge drug research with practical emergency care improvements.
Digestive System Diseases
The gastroenterology unit focuses on chronic inflammatory bowel conditions, including Crohn's disease and ulcerative colitis. Ongoing studies evaluate oral therapies that aim to induce remission and maintain long‑term disease control.
- Testing a novel oral anti‑inflammatory for ulcerative colitis
- Assessing maintenance dosing of a Janus kinase inhibitor in Crohn's disease
- Monitoring safety of long‑term treatment extensions
- Measuring patient‑reported outcomes and quality of life
These investigations seek to expand therapeutic options for patients living with digestive system disorders.
Female Urogenital Diseases and Pregnancy Complications
A targeted trial at Herlev Hospital examines care after obstetric perineal rupture. The study looks at whether a short course of oral antibiotics can lower infection rates and support better wound healing for new mothers.
- Preventing postoperative infection in perineal tears
- Reducing wound dehiscence through prophylactic antibiotics
- Evaluating safety for mother and infant
- Collecting data on recovery time and comfort
This research reflects the department’s commitment to improving maternal health outcomes.
Immune System Diseases
Investigations into the immune response are underway, featuring trials that combine experimental agents such as IO102‑IO103 with established immunotherapies like pembrolizumab. The goal is to boost tumor‑killing activity before surgery.
- Measuring major pathological response to neoadjuvant immunotherapy
- Comparing outcomes of combination versus standard treatment
- Analyzing biomarkers of immune activation
- Tracking postoperative recovery and side‑effect profile
These studies aim to refine how the immune system can be harnessed to fight cancer more effectively.
Neoplasms
The oncology‑focused projects at Herlev Hospital address solid tumours such as melanoma and squamous cell carcinoma of the head and neck. Researchers are testing whether postoperative immunotherapy can prevent disease recurrence after complete tumor removal.
- Evaluating recurrence‑free survival with checkpoint inhibitors
- Assessing the impact of adjuvant therapy on long‑term outcomes
- Studying safety and tolerability in resected patients
- Collecting quality‑of‑life data during follow‑up
The work contributes to advancing treatment standards for patients with high‑risk cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 27 therapeutic areas and 15 of 409 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 373 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 62 by active trials.
- 1Region Hovedstaden21active
lock +61 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC30trials
lock +37 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Herlev Hospital
lock Showing 1 of 296 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Feb 2016 | — |
IMP list
lock Showing 1 of 409 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 31 | Unknown | 2015-07-16 | 2026-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.